Tumor-specific activity of cellular regulatory elements is down-regulated upon insertion into the herpes simplex virus genome

Journal of NeuroVirology

Volumn 14, Issue 6, 2008, Pages 522-535

  Glasß, Mandy ^a,b   Soling, Ariane ^c   Messerle, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Glioblastoma; Oncolytic herpesvirus; Transcriptional targeting; Viral gene regulation

Indexed keywords

MESSENGER RNA; NESTIN; ONCOLYTIC VIRUS; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; VASCULOTROPIN A; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; INTERMEDIATE FILAMENT PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NERVE PROTEIN; NES PROTEIN, HUMAN; NES PROTEIN, RAT; TELOMERASE;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENHANCER REGION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLIOMA; GLIOMA CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; ANIMAL; ANTIBODY SPECIFICITY; BRAIN NEOPLASMS; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; ONCOLYTIC VIROTHERAPY; PROCEDURES; RAT; REGULATORY SEQUENCE; TUMOR CELL LINE;

HERPESVIRIDAE; HUMAN HERPESVIRUS 1; SIMIAN VIRUS 40; SIMPLEXVIRUS;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; GENETIC VECTORS; GENOME, VIRAL; GLIOBLASTOMA; HERPESVIRUS 1, HUMAN; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERMEDIATE FILAMENT PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NERVE TISSUE PROTEINS; NESTIN; ONCOLYTIC VIROTHERAPY; ORGAN SPECIFICITY; RATS; REGULATORY ELEMENTS, TRANSCRIPTIONAL; TELOMERASE; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 69949125187     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280802348214     Document Type: Article

References (53)

1. Aghi M, Martuza RL (2005). Oncolytic viral therapies - the clinical experience. Oncogene 24: 7802-7816.
2. Ambrosini G, Adida C, Altieri DC (1997). A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921.
3. Asai A, Miyagi Y, Sugiyama A, Gamanuma M, Hong SH, Takamoto S, Nomura K, Matsutani M, Takakura K, Kuchino Y (1994). Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J Neurooncol 19: 259-268.
4. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW (1996). Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 56: 645-650.
5. Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, Hamilton TC (2002). Activation of cancerspecific gene expression by the survivin promoter. J Natl Cancer Inst 94: 522-528.
6. Boldrini L, Pistolesi S, Gisfredi S, Ursino S, Ali G, Pieracci N, Basolo F, Parenti G, Fontanini G (2006). Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol 28: 1555-1560.
7. Borst EM, Messerle M (2005). Analysis of human cytomegalovirus oriLyt sequence requirements in the context of the viral genome. J Virol 79: 3615-3626.
8. Carmeliet P, Jain RK (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257.
9. Chaudhry IH, O'Donovan DG, Brenchley PE, Reid H, Roberts IS (2001). Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39: 409-415.
10. Chen B, Timiryasova TM, Haghighat P, Andres ML, Kajioka EH, Dutta-Roy R, Gridley DS, Fodor I (2001). Low-dose vaccinia virus-mediated cytokine gene therapy of glioma. J Immunother 24: 46-57.
11. Cherepanov PP,WackernagelW(1995). Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibioticresistance determinant. Gene 158: 9-14.
12. Chung RY, Saeki Y, Chiocca EA (1999). B-myb promoter retargeting of herpes simplex virus gamma34.5 genemediated virulence toward tumor and cycling cells. J Virol 73: 7556-7564.
13. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, Zanusso M, PalùG (2005). Combined HSVTK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: Biological and clinical results. Cancer Gene Ther 12: 835-848.
14. Dahlstrand J, Collins VP, Lendahl U (1992). Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 52: 5334- 5341.
15. Datsenko KA, Wanner BL (2000). One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97: 6640-6645.
16. Dohner K, Wolfstein A, Prank U, Echeverri C, Dujardin D, Vallee R, Sodeik B (2002). Function of dynein and dynactin in herpes simplex virus capsid transport. Mol Biol Cell 13: 2795-2809.
17. Falchetti ML, Larocca LM, Pallini R (2002). Telomerase in brain tumors. Childs Nerv Syst 18: 112-117.
18. Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M, Hadley D, Patterson J, Brown SM, Rampling R (2004). HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival. Gene Ther 11: 1648-1658.
19. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M (2002). Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247- 3257.
20. Johe KK, Hazel TG, Muller T, Dugich-Djordjevic MM, McKay RD (1996). Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Genes Dev 10: 3129-3140.
21. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K (2003). Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97: 1077-1083.
22. Kambara H, Okano H, Chiocca EA, Saeki Y (2005). An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832-2839.
23. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002). The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225.
24. Kurihara H, Zama A, Tamura M, Takeda J, Sasaki T, Takeuchi T (2000). Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator. Gene Ther 7: 686-693.
25. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001). A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 95: 190-198.
26. Lendahl U, Zimmerman LB, McKay RD (1990). CNS stem cells express a new class of intermediate filament protein. Cell 60: 585-595.
27. Leopardi R, Van Sant C, Roizman B (1997). The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus. Proc Natl Acad Sci U S A 94: 7891-7896.
28. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Israel MA (2005). Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102: 5814-5819.
29. Liang Y, Li XY, Rebar EJ, Li P, Zhou Y, Chen B, Wolffe AP, Case CC (2002). Activation of vascular endothelial growth factor A transcription in tumorigenic glioblastoma cell lines by an enhancer with cell type-specific DNase I accessibility. J Biol Chem 277: 20087-20094.
30. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
31. Lothian C, Lendahl U (1997). An evolutionarily conserved region in the second intron of the human nestin gene directs gene expression to CNS progenitor cells and to early neural crest cells. Eur J Neurosci 9: 452-462.
32. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL (2000). Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 7: 867-874.
33. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB, Brooks MW, Kaneko S, Murakami S, DeCaprio JA, Weinberg RA, Stewart SA, Hahn WC (2003). Telomerase maintains telomere structure in normal human cells. Cell 114: 241-253.
34. McCarthy KD, de Vellis J (1980). Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890-902.
35. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622.
36. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P (2004). Genetic pathways to glioblastoma: A population-based study. Cancer Res 64: 6892-6899.
37. Parato KA, Senger D, Forsyth PA, Bell JC (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5 965-976.
38. Poole JC, Andrews LG, Tollefsbol TO (2001). Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 269: 1-12.
39. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R, Brown M (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859-866.
40. Roizman B (2001). Herpes simplex viruses and their replication. In: Fields virology, Knipe DM, Howley PM (eds). Lippincott Williams & Wilkins: Philadelphia, US. pp. 2432-2435.
41. Rong Y, Durden DL, Van Meir EG, Brat DJ (2006). 'Pseudopalisading' necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65: 529-539.
42. Rutka JT, Ivanchuk S, Mondal S, Taylor M, Sakai K, Dirks P, Jun P, Jung S, Becker LE, Ackerley C (1999). Coexpression of nestin and vimentin intermediate filaments in invasive human astrocytoma cells. Int J Dev Neurosci 17: 503-515.
43. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, Kononen J (2000). Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60: 6617-6622.
44. Song JS (2004). Activity of the human telomerase catalytic subunit (hTERT) gene promoter could be increased by the SV40 enhancer. Biosci Biotechnol Biochem 68: 1634-1639.
45. Stangel M, Bernard D (2003). Polyclonal IgM influence oligodendrocyte precursor cells in mixed glial cell cultures: Implications for remyelination. J Neuroimmunol 138: 25-30.
46. Stewart LA (2002). Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018.
47. Strojnik T, Kavalar R, Lah TT (2006). Experimental model and immunohistochemical analyses of U87 human glioblastoma cell xenografts in immunosuppressed rat brains. Anticancer Res 26: 2887-2900.
48. Tanaka M, Kagawa H, Yamanashi Y, Sata T, Kawaguchi Y (2003a). Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: Viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo. J Virol 77: 1382-1391.
49. Tanaka S, Kobayashi I, Utsuki S, Oka H, Fujii K, Watanabe T, Nagashima T, Hori T (2003b). O6-methylguanine- DNA methyltranspherase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. Int J Cancer 103: 67-72.
50. Vogel TW, Zhuang Z, Li J, Okamoto H, Furuta M, Lee YS, Zeng W, Oldfield EH, Vortmeyer AO, Weil RJ (2005). Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res 11: 3624-3632.
51. Xu D, Wang Q, Gruber A, Bjorkholm M, Chen Z, Zaid A, Selivanova G, Peterson C, Wiman KG, Pisa P (2000). Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 19: 5123-5133.
52. Yancopoulos GD, Davis S, Gale NW, Rudge JS,Wiegand SJ, Holash J (2000). Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248.
53. Zaman GJ, Conway EM (2000). The elusive factor Xa receptor: Failure to detect transcripts that correspond to the published sequence of EPR-1. Blood 96: 145-148.